John,

Join Health Affairs February 25 for an Insider-exclusive virtual event exploring HHS’s announcement of the 15 additional drugs selected for Medicare drug price negotiations, including weight-loss drugs such as Ozempic and Wegovy.

This event is for Health Affairs Insiders only.

Insider is Health Affairs’ membership program that deepens your health policy expertise. Insider's events offer perspectives from experienced health policy experts and are tailored to help you gain insights that elevate your work.

New Drugs at the Medicare Negotiating Table with Stacie Dusetzina

In the final days of the Biden administration, CMS revealed the second round of drugs selected for Medicare drug price negotiations under the Inflation Reduction Act.

Among the 15 drugs selected are treatments for conditions, such as cancer, type 2 diabetes, and asthma. This round also includes blockbuster weight-loss-associated drugs Ozempic, Rybelsus, and Wegovy.

Stacie Dusetzina, professor of health policy at Vanderbilt University Medical Center and Health Affairs Insider newsletter writer, joins Health Affairs’ Laura Tollen to get Insiders up to speed on this round of drugs, the negotiation process to come, and what to expect in the second Trump administration.

Dusetzina and Tollen will discuss the topic for 15 minutes before opening up a 15-minute Q&A session for attendees.

Date: February 25, 2025 

Time: 2 pm – 2:30 pm ET 

If you have accessibility or support requirements in order to participate fully in this event, please contact [email protected] to ensure that we can arrange reasonable accommodations. 

Sign up for our free daily and weekly newsletters to never miss an event, an article, podcast, or health policy brief.